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50 Abstract 
51 Objective: Modality and frequency of image-based renal cell carcinoma (RCC) follow-up (FU) strategies are 
52 based on risk of recurrence.  Using the RECUR-database; we studied frequency of imaging in regard to 
53 prognostic risk groups. Furthermore, whether imaging modality utilised in contemporary FU were 
54 associated with outcome after detection of recurrence. Moreover, we compared outcome based on 
55 whether the assessment of potential curability was a predefined set of criteria’s (per-protocol`) or stated by 
56 the investigator.
57 Materials and Methods: Consecutive non-metastatic RCC patients (n=1,612) treated with curative intent at 
58 12 institutes across 8 European countries between 2006 and 2011 were included. Leibovich or UISS risk 
59 group, recurrence characteristics, imaging modality, frequency and survival were recorded. Primary 
60 endpoints were overall survival (OS) after detection of recurrence and frequency of features associated 
61 with favourable outcome (non-symptomatic recurrences and detection within the FU-program). 
62
63 Results: Recurrence occurred in 336 patients. Within low, intermediate and high risk for recurrence groups, 
64 the frequency of FU imaging was highest in the early phase of FU, and decreased significantly over time 
65 (p<0.001). However, neither the image modality for detection nor ≥50% cross-sectional imaging during FU, 
66 were associated with improved OS after recurrence. Differences between per protocol and investigator 
67 based assessment of curability, did not translate into differences in OS.
68 Conclusions: As expected, the frequency of imaging was highest during early follow-up. Cross-sectional 
69 imaging use for detection of recurrences following surgery for localised RCC did not improve OS post-
70 recurrence. Prospective studies are needed to determine the value of imaging in follow-up.
71 N=249 (max. 250) 
72
73
74
75
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82 1. Introduction
83 Among the purposes for follow-up after radical treatment of RCC are observation of renal function, 
84 recovery from surgery, oncological control to detect recurrence of disease manifestations and finally, a 
85 psychosocial need for both patient and physician following cancer treatment [1].
86 It seems deeply rooted that early detection of cancer recurrences results in more effective treatment 
87 which improves survival. Based on this assumption, most of the readily used RCC follow-up strategies 
88 adapt their imaging modality and frequency to the risk and potential site of recurrence [2-4]. During 
89 the last decades, this risk-based approach to follow-up has resulted in increased recommendations for 
90 follow-up imaging and subsequently an increased use of cross-sectional imaging in RCC follow-up [2, 5-
91 12]. The literature investigating the impact of follow-up imaging after RCC treatment is limited [13-15], 
92 but a recent study failed to show superiority in regard to post-recurrence survival for more intensive 
93 use of follow-up imaging [12]. However, to our knowledge, there are no comparative studies exploring 
94 if a specific imaging modality actually translates into improved overall survival after RCC recurrence.
95 The European Association of Urology (EAU) RCC Guidelines Panel has established a collaborative 
96 multicentre consortium (RECUR) to investigate comparators for evidence-based follow-up 
97 recommendation for localized RCC. In contrast to previously published follow-up studies, the focus of 
98 RECUR is on further management and outcome once a recurrence is detected. To achieve uniform 
99 definitions for comparisons between groups, the RECUR database utilizes per protocol-based data 
100 collection. However, arbitrary global per protocol assessments of potential curability of RCC 
101 recurrence may be disputed, and as such an investigator based assessment of curability is also 
102 registered in the RECUR database.
103 The aim of the present study was primarily to describe contemporary frequencies of follow-up imaging 
104 stratified by risk of recurrence groups. Secondly, to look for potential differences in outcome after 
105 recurrence, based on the imaging modalities used for follow-up and recurrence detection. Finally, to 
106 explore if there were significant differences in the outcome results dependent on use of global per 
107 protocol or investigator based assessments of curability of the recurrences.
108
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109 2. Materials and Methods
110 2.1.The RECUR-database, quality assurance, exclusions and ethical considerations
111 RECUR collected data from 1889 patients with localised RCC from 12 centres (all with appropriate 
112 institutional approval) in 8 European countries (see supplementary text) in this current study. Eligible 
113 patients underwent surgery with curative intent from January 2006 (the start of the Tyrosine kinase 
114 inhibitor era) to December 2011, allowing for a minimum of 4 years of follow-up for patients still alive 
115 and without recurrence at inclusion in the study. All data were audited for quality and completeness by 
116 a urological surgeon (SD). After exclusions (figure 1), the final study population consisted of 1612 
117 patients for the current analysis. The median follow-up for patients who did not experience recurrence 
118 or died was 63 months (IQR 58–76). Patient characteristics are shown in table 1. 
119
120 2.2.Definitions used for analyses
121 The validated risk grouping system described by Leibovich [16, 17] was used for clear cell RCC while the 
122 University of California Los Angeles Integrated Staging System (UISS) system [18] was used for non-clear 
123 cell RCC. Overall survival after recurrence was defined as the time from recurrence until death of any 
124 cause or, for patients still alive, to the date of last FU.
125
126 Imaging frequency was defined as the total number of imaging studies during follow-up until 
127 recurrence or last follow-up, divided by years of follow-up. As most of the institutional FU imaging 
128 strategies utilized were both risk-and time-dependent, with more imaging in the early years after 
129 treatment, we devised three follow-up groups (follow-up until recurrence or last follow-up or death of 
130 other causes): short-term follow-up (0-2.49 years), mid-term follow-up (2.5-5.49 years) and long-term 
131 follow-up (>5.5 years)) after treatment of primary tumor for all three risk groups, resulting in nine 
132 patient groups.
133
134 Methods of imaging were cross-sectional imaging (CSI; computerized tomography (CT) or magnetic 
135 resonance imaging (MRI)) or conventional (chest x-ray (CXR) or ultrasound (US)). Ratio`s for abdominal 
136 and thoracic imaging were calculated by dividing cross-sectional by conventional imaging.
137 All patients were further divided into two groups depending on their CSI percentage of the total 
138 number of imaging tests (≥50% vs. <50%). The cut point for dichotomisation was chosen for simplicity 
139 as it was close to the median.
140
141 The primary endpoints were detection of recurrence either as non-symptomatic or detection within 
142 institutional follow-up, as this may serve as surrogate indicators of improved outcome after recurrence 
143 [19]. Secondary analyses were: (i) the relationship between the primary endpoints and methods of 
144 imaging during FU; and (ii) the correlation between methods of imaging and overall survival after 
145 recurrence. 
146
147 The global per protocol definition of a potentially curable (PC) RCC recurrence was, as previously 
148 published [12, 19], taken to be local recurrence, single metastasis or oligometastasis (≤3 lesions at a 
149 single site). All other recurrences were considered probably incurable (PI). Additionally, the investigator 
150 based assessment of each patient with recurrence (investigator based assessment based PC or PI) were 
151 also established by an investigator from each contributing RECUR institute.
152
153
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154 2.3.Statistical analysis
155 Descriptive statistics were presented as categorical variables with percentages and continuous 
156 variables as median and interquartile range (IQR). For categorical and non-parametric data, exact Chi-
157 square test and Mann-Whitney U-test or Kruskal-Wallis test, respectively, were used. Correlation for 
158 group allocation for PC/PI was evaluated with Kappa statistics. Kaplan-Meier method with Log-Rank 
159 test was performed for overall survival. For all statistical comparisons, a two-tailed p-value of <0.05 was 
160 considered significant. SPSS-version 23 (IBM corporation, Armonk, New York, USA) and R version 3.3.2 
161 (R Foundation for Statistical Computing, Vienna, Austria) were used.
162
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163 3. Results 
164 3.1. Imaging modalities and frequencies
165 Of 17,333 follow-up imaging procedures performed, 4,929 (28%) were CT Abdomen (CTA), 3024 (17%) 
166 CT Thorax (CTT), 6,540 (38%) CXR, 2,651 (15%) US and 189 (1.1%) abdominal MRIs. The CTT:CXR-ratio 
167 decreased significantly across the risk groups, and was 1.0, 0.46 and 0.35 in the high, intermediate and 
168 low risk group, respectively (p<0.001). Moreover, the overall CTA:US-ratio also decreased from the 
169 high to the low RG (3.2, 1.7 and 1.7, respectively; p<0.001)(table 2). 
170 Irrespective of risk group, the highest frequency of imaging was during early follow-up, and decreased 
171 significantly with longer follow-up (overall p<0.001). The median frequency of imaging increased with 
172 increasing risk group allocation in all follow-up groups. The frequency of imaging was not significantly 
173 different between patients who developed recurrences and those who did not, except for the mid-
174 term follow-up group of high risk group patients, where those with recurrences underwent more 
175 imaging (p=0.002; table 3).
176
177 3.2. Recurrences and outcome
178 Recurrences were detected by CSI in 257 of 336 patients (76%), and 210 patients (63%) had >50% of 
179 their follow-up imaging performed by CSI. In the low and intermediate risk groups, more recurrences 
180 were detected as part of regular follow-up when >50% CSI was performed during follow-up. The 
181 difference, however, was only statistically significant for the intermediate risk group (table 4). For 
182 detection of non-symptomatic recurrences, no significant difference was seen between the high and 
183 low CSI group (table 4).
184 There was a non-significant tendency towards more recurrences being detected via routine follow-up 
185 and being non-symptomatic at detection if the frequency of imaging was above median rather than 
186 below the median (see supplementary table 1).
187 There was no significant difference in overall survival between PC and PI patients stratified for the type 
188 of imaging resulting in detection of their recurrence (figure 2a). Similarly, neither was there any 
189 significant difference in overall survival after recurrence based on high (≥50%) or low (<50%) CSI 
190 percentage during follow-up (figure 2b). Moreover, exploratory analyses with quartiles for CSI 
191 frequencies gave in similar results. 
192
193 3.3. Global per protocol assessment vs. Investigator based assessment of curability
194 Of 336 recurrences, by the global per protocol definition of recurrence curability, 152 (45%) were 
195 classified as PC, while the remaining 184 (55%), with multiple metastases, were considered PI. When 
196 applying the investigator based assessment of recurrence curability, the numbers were 123 (37%) and 
197 213 (63%) for PC and PI, respectively.  Investigator based assessment classified 40 PC patients as PI and 
198 11 PI patients as PC. The kappa value for the scoring was 0.69. 
199 In 20 of 70 solitary, 16 of 38 oligometastatic and 4 of 25 local recurrences, investigator based 
200 assessment classified them as PI rather than PC. These patients were older (68 years vs. 65 years, 
201 p=0.102), and in approximately 50% of cases there was an investigator’s note in the RECUR database 
202 stating comorbidity and/or patient’s wishes prohibiting curative intended procedures 
203 (surgery/ablation/radiation (i.e. stereotactic radiotherapy)). Kaplan-Meier estimates showed that the 
204 median overall survival for PC patients was 50 months vs. 43 months for the investigator based 
205 assessment and global per protocol groups, respectively (p=0.2) (figure 3). For PI patients the median 
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206 overall survival was 16 months for both the investigator based assessment and global per protocol 
207 assessment. 
208
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209 4. Discussion
210 It is generally believed that regular imaging has the potential to reveal recurrences early while small 
211 and asymptomatic. However, for such imaging strategies to be useful the disease has to behave in a 
212 predictable pattern in the majority of patients, with recurrences growing linearly, disseminating to 
213 predetermined sites and in a predictable fashion. We have previously shown that only 2% of patients 
214 with initially localised RCC in the high RG will, after recurrence detection, remain disease free after 
215 resection of recurrence [19]. In this study we showed that the frequency of cross-sectional imaging and 
216 mode of imaging at detection for patients with recurrent disease had no bearing on the oncological 
217 outcome. 
218
219 Imaging in most cancer follow-up protocols follows defined intervals and with the highest frequency in 
220 periods for which historic data have shown that recurrences are most likely to be diagnosed. Our 
221 results demonstrate that the participating institutions, during the study period, used follow-up imaging 
222 relatively similar to the present recommendations from EAU [3],both in regard to use of imaging based 
223 on risk stratification and the duration of follow-up. As the frequency of imaging for RCC patients 
224 developing recurrence and those remaining disease free is relatively similar, our figures most likely 
225 represent the daily practice at the institutions.
226 In the 2017 edition, the EAU RCC guidelines removed CXR from the follow-up recommendation. The 
227 present study in patients treated between 2006 to 2011, shows that CXR was the most used modality 
228 for investigation of the thorax. Similarly, the use of ultrasound was more frequent than recommended 
229 by the EAU guidelines. With the updated recommendations in mind, it is intriguing that imaging 
230 modality utilised does not seem to translate into a survival benefit. If no gain can be identified by the 
231 use of CTT instead of CXR, questions about cost-effectiveness and increased radiation exposure may 
232 be justified.
233 It is well documented that micrometastatic RCC cells may remain dormant for a long time before they 
234 develop into macroscopic, detectable disease. The reasons for dormancy may be multiple [20]; 
235 including genomic classification [21], inability to recruit blood vessels, immune surveillance, cell cycle 
236 arrest or tumor microenvironment interactions. There may be several causes for these disease foci to 
237 start growing at some time point. Some of these are tumor regulated such as the onset of 
238 chromosomal instability [22], but they may also be triggered by external factors such as other diseases 
239 and surgical [23] or other traumas (e.g. fractures or other traumatic injuries). It is hypothesized that 
240 increased levels of growth factors may stimulate several dormant tumors at the same time, resulting in 
241 disseminated visible metastatic disease in a short period of time [23, 24].  Moreover, unlike some 
242 other cancers with predicable patterns of recurrence, e.g. prostate cancer, RCC has the potential to 
243 metastasize to most organs. The sites of RCC recurrences not covered by CT of the thorax and 
244 abdomen are not negligible and up to 16% is reported [25]. Hence, such an image based FU program 
245 has an a priori inherent failure rate. Furthermore, these recurrences will in most cases be detected as 
246 symptomatic, with known poorer prognosis [25, 26]. 
247 Within the RECUR collaboration, a global per protocol assessment of potential curability has been 
248 established [12, 19]. The definite advantage of this methodology is that it only accounts for disease 
249 related factors such as type and number of metastatic sites, and is thus uniform and reproducible. In 
250 contrast, an investigator based assessment is subjective and appears to be affected by both disease 
251 and patient related factors like age, comorbidity and patients choices. In our opinion, and especially in 
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252 a retrospective setting, the need for limitation of potential confounders are important and might be 
253 better solved by a per protocol approach. However, for a study to be considered valid and useful, the 
254 results need to be recognized by clinicians. Therefore, to reconcile a per protocol assessment to an 
255 investigator based assessment is important. In this study, we found differences in the assessment, but 
256 these did not translate into significant differences in overall survival post recurrence for the PC and PI 
257 groups. In our opinion, these results reinforce the decision to use a per protocol assessment of 
258 curability within RECUR.
259 As our study is retrospective, and thus has obvious limitations, interpretations must be made with 
260 caution. All RECUR institutes used their own follow-up protocols with varying intervals between each 
261 imaging performed. Therefore, it was not possible to demonstrate to what extent each patient 
262 underwent imaging at the recommended time point. We acknowledge that CT detects lesions with 
263 higher resolution than ultrasound/CXR [27]. However, there is little evidence that CT have impacted 
264 the results significantly. The fact that all histological RCC subtypes were included in the current 
265 analysis may be a further limitation. Indeed there are published histological subtype-specific follow-up 
266 strategies but nevertheless, the major guidelines (EAU, AUA and NCCN) currently continue to provide 
267 FU strategies indiscriminately of RCC subtype [2-4].
268 The present study did not evaluate quality of life aspects. Follow-up definitely serves a psychosocial 
269 need which may be as important as the aspect of oncological control. Anxiety after surgery for cancer 
270 leaves patients with a timely reassurance that they remain free of disease. Therefore some kind of 
271 routine follow-up is probably indicated. However, the present study questions the need to increase 
272 the use of static and regular follow-up imaging. 
273 It is likely that improved risk stratification tools will become available. Several molecular panels have 
274 shown prognostic utility [28-30]. Competing risk analyses have been introduced for tailoring follow-up 
275 programs to the individual patient factoring in age and comorbidities [19, 31], suggesting that routine 
276 follow-up be reduced in patients were the risk of death of other causes supersedes the risk of dying 
277 from RCC. The future of RCC follow-up is most likely to be much more personalized and routine follow-
278 up will be replaced by tailored imaging during periods when recurrences are most likely to occur. 
279 Moreover, in the future, new follow-up programmes will have to be cost-effective [32].    
280
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281 5. Conclusion
282 The present study suggests that the mode of imaging for follow-up, detection of recurrences and the 
283 frequency at which imaging is applied do not affect subsequent overall survival. Prospective studies 
284 are needed to confirm these findings and help design optimal follow-up strategies which may be less 
285 intense but more personalised than those currently used.
286
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287 6. Figure legends
288 Figure 1. Flowchart demonstrating inclusion and exclusion criteria for the present study.
289
290 Figure 2. 
291 a) Kaplan-Meier plots for overall survival after recurrences for patients stratified on curability and 
292 their recurrence detected by conventional (Conv-continuous lines) methods or cross sectional 
293 imaging (CSI-dotted lines). There was no significant difference within the potential curable (PC-
294 red) or the probably incurable (PI-black) group.
295 b) Kaplan-Meier plots for overall survival after recurrences for patients stratified on curability and 
296 if the majority of follow-op imaging was by conventional (<50% CSI-dotted) methods or cross 
297 sectional imaging (≥50% CSI-continuous lines). There was no significant difference within the 
298 potential curable (PC-red) or the probably incurable (PI-black) group
299
300
301 Figure 3. 
302 a) Kaplan-Meier plots for overall survival after recurrences for patients stratified on curability and 
303 their recurrence classified by global per protocol (GPP-continuous lines) assessment or by 
304 investigator based assessment (IBA-dotted lines). There was no significant difference within the 
305 potential curable (PC-red) or the probably incurable (PI-black) group.
306
307
308
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Table 1.  Patient characteristics (n=1,612)
n-number of patients, yrs-years,  SEM-standard error of the mean, IQR-Inter Quartile Range, cm-centimeter, 
RCC-Renal cell carcinoma, pT-pathological tumor stage, pN-pathological lymph node stage, *- for clear cell 
RCC the risk group allocation is based on the system by Leibovich [16] and for non-clear cell RCC by the UISS 
system [18].
n %
Age (yrs) - Mean (median, IQR) 62.9 (64.0, 55-72)
Gender Male 1036 64.3
Female 576 35.7
Tumour size (cm) - Mean (median, IQR) 5.9 (5.0, 3-8)
RCC Subtype Clear Cell RCC 1227 76.1
Papillary RCC 233 14.5
Chromophobe RCC 113 7.0
Other RCC 39 2.4
Primary pT-stage pT1a 590 36.6
pT1b 395 24.5
pT2a 161 10.0
pT2b 101 6,3
pT3a 276 17.1
pT3b 70 4,3
pT3c 6 0.4
pT4 13 0.8
Primary pN-stage pNx-0 1579 98.0
pN1-2 33 2.0
Risk group* High 309 19.2
Intermediate 497 30.8
Low 806 50.0
Surgical procedure Radical nephrectomy 1141 70.8
Partial nephrectomy 471 29.2
Recurrences by  presentation (n=336) Symptomatic 125 37.2
Asymptomatic 211 62.8
Yes 238 70.8Recurrences detected by regular follow-up 
(n=336) No 98 29.2
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Table 2. The table demonstrates the use of follow-up imaging for the three risk groups of RCC in the RECUR-cohort. 
CT – Computer tomography, CXR – Chest X-ray, US – Ultrasound, MRI – Magnetic Resonance Imaging, n- Number, Exact Chi-square test 
demonstrates that the distribution of CT and conventional imaging is statistically significant different (p<0.001) between the different risk groups 
for both thoracal and abdominal imaging. The only exception is between the low risk and intermediate risk group for abdominal imaging
Imaging
Thoracal imaging Abdominal imagingTotal CT CXR CT US MRIRisk Groups
n n n
CT/ CXR 
Ratio n n
CT/US 
Ratio n
Low                                   (n=806) 8986 1300 3694 0.35 2445 1439 1.70 108
Intermediate                 (n=497) 5560 951 2071 0.46 1554 921 1.69 63
High                                  (n=309) 2787 773 775 1.00 930 291 3.20 18
Total                                 (n=1612) 17333 3024 6540 0.46 4929 2651 1.86 189
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Table 3. Frequency of imaging (images per year) by Risk groups and groups of follow-up
Groups of Follow-Up (FU)
Short-term FU (0 – 2.49 yrs, n=292) Mid-term FU (2.5 – 5.49 yrs, n=846) Long-term FU (> 5.5 yrs, n=482) p-valuea
n
IF 
Median (IQR) p-valuec n
IF
Median (IQR) p-valuec n
IF
Median (IQR) p-valuecRisk Group (RG)
LOW RG (n=806) 60 3.3 (1.6-6.3) 490 2.2 (1.8-2.6) 256 1.7 (1.2-2.4) <0.001
Recurrences 20 4.6 (2.6-6.7) 35 2.0 (1.5-2.8) 10 1.7 (1.3-2.4)
Non-recurrences 40 2.4 (1.3-5.4) 0.064 455 2.2 (1.8-2.6) 0.458 246 1.7 (1.2-2.4) 0.754
INTERM. RG (n=497) 92 3.9 (2.7-4.7) 242 2.3 (1.9-2.9) 163 2.0 (1.3-2.6) <0.001
Recurrences 63 3.8 (3.0-4.5) 37 2.5 (1.8-3.4) 8 1.6 (0.6-2.2)
Non-recurrences 29 4.0 (2.0-6.1) 0.930 205 2.3 (1.9-2-8) 0.355 155 2.1 (1.3-2.6) 0.211
HIGH RG (n=309) 132 4.4 (3.0-6.1) 114 2.6 (2.1-3.3) 63 2.0 (1.3-2.6) <0.001
Recurrences 123 4.4 (3.0-6.0) 36 3.2 (2.3-4.2) 4 2.3 (0.8-3.8)
Non-recurrences 9 3.2 (1.8-6.3) 0.524 78 2.5 (1.8-3.1) 0.002 59 2.0 (1.3-2.4) 0.796
p-valueb 0.084d <0.001 0.057e
IF – Imaging Frequency, IQR – interquartile range, n-numbers of patients, a – Non-parametric Kruskal-Wallis test for equal distribution of imaging frequency 
within each risk group across all periods of follow-up, b - Non-parametric Kruskal-Wallis test for equal distribution of imaging frequency within each period of 
follow-up across all risk groups, c – Mann-Whitney U-test for equal distribution of imaging frequency between patients with and without recurrences grouped 
by risk group and group of follow-up, d – testing two and two categories by MWU-test demonstrated that none of the three groups had a significant different IF 
distribution, e - testing two and two categories by MWU-test demonstrated that IF in the late FU-group of the LRG was significantly lower than for the IRG 
(p=0.029), none of the other comparisons demonstrated significant differences. Non-recurrences in the Short-term FU group are patients dead of other causes.
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Table 4. Patient features divided by high CSI (≥50% CSI) and low CSI (<50% CSI) during FU.
CSI – Cross sectional Imaging, n – number of patients, a – exact Chi-square test, Detected in 
reg. FU – detected in regular follow-up program. Recurr. – recurrence. 
The figures for patients not detected in regular FU and with symptomatic recurrences are not 
shown, but can be calculated from the presented data.
Risk group n Feature <50% CSI ≥50% CSI p-valuea
65 Detected in reg. FU 15 (50%) 24 (69%) 0.204Low Risk Non-Symptomatic recurr. 15 (50%) 25 (71%) 0.124
108 Detected in reg. FU 30 (58%) 48 (86%) 0.001Intermediate
Risk Non-Symptomatic recurr. 32 (62%) 40 (71%) 0.311
163 Detected in reg. FU 31 (70%) 90 (76%) 0.547High Risk Non-Symptomatic recurr. 30 (68%) 69 (58%) 0.280
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12 European hospital 
databases  for  RCC 
patients
RECUR database         
n=1665
Inclusion critera
  Per RECUR-protocol (see supplementaries), including:
- RCC (All subtypes)
- Surgically treated with curative intent between 
01.01.2006 and 31.12.2011
- Non-metastatic (M0)
- At least 4 year of follow-up (unless death or reccurent 
RCC)
n=53 - Incomplete datasets for imaging during follow-up
Study population        
n=1612
Non recurrent              
n=1276
Manual quality assesment                 
n=1889
n=224
- Death within 90 days of surgery (n=7)
- < 4 years of follow-up (n=111)
- Incomplete datasets (n=106)
Inclusion into RECUR-database
Exclusion
Exclusion
Figure 1
Recurrences                
n=336
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Supplementary table 1. Patient features divided by high IF (above median) and low IF (below 
median) at the time of recurrence.
IF – imaging Frequency, Gofu – Group of follow-up, n – number of patients, a – exact Chi-
square test, Detected in reg. FU – detected in regular follow-up program. Recurr. – 
recurrence.
The figures for patients not detected in regular FU and with symptomatic recurrences are not 
shown, but can be calculated from the presented data.
Risk Group GoFU n Feature Low IF High IF p-valuea
20 Detected in reg. FU 4 (57%) 9 (69%) 0.651Short-
term FU Non-Symptomatic recurr. 5 (71%) 10 (77%) 1.000
35 Detected in reg. FU 10 (53%) 12 (75%) 0.293Mid-
term FU Non-Symptomatic recurr. 10 (53%) 12 (75%) 0.293
10 Detected in reg. FU 3 (50%) 1 (25%) 0.571
Low Risk
Long-
term FU Non-Symptomatic recurr. 2 (33%) 1 (25%) 1.000
63 Detected in reg. FU 21 (66%) 29 (94%) 0.011Short-
term FU Non-Symptomatic recurr. 20 (63%) 26 (84%) 0.088
37 Detected in reg. FU 12 (75%) 9 (67%) 0.723Mid-
term FU Non-Symptomatic recurr. 11 (69%) 3 (62%) 1.000
8 Detected in reg. FU 1 (20%) 1 (33%) 1.000
Intermed. 
Risk
Long-
term FU Non-Symptomatic recurr. 1 (20%) 1 (33%) 1.000
123 Detected in reg. FU 40 (61%) 9 (81%) 0.069Short-
term FU Non-Symptomatic recurr. 31 (51%) 37 (62%) 0.367
36 Detected in reg. FU 13 (93%) 17 (77%) 0.370Mid-
term FU Non-Symptomatic recurr. 14 (100%) 16 (73%) 0.062
4 Detected in reg. FU 0 (0%) 1 (50%) 1.000
High Risk
Long-
term FU Non-Symptomatic recurr. 0 (0%) 1 (50%) 1.000
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Dabestani, Beisland et al. (2019); Increased use of cross-
sectional imaging for follow-up does not improve post-
recurrence survival of surgically treated initially localized RCC: 
results from a European multicenter database (RECUR).
SUPPLEMENTARY TEXT (Materials and Methods – Expanded chapters)
The RECUR – Database (description of Ethics, Inclusion, Exclusion, Coding of data – this 
chapter is mostly similar to the supplementary text of the earlier RECUR-papers [1, 2]
The current study is the second study performed under the auspices of the euRopEan association of 
urology renal cell carcinoma guidelines panel Collaborative multicenter consortium for the studies of 
follow-Up and recurrence patterns in Radically treated renal cell carcinoma patients (RECUR). The full 
RECUR protocol is available as an online appendix to the first paper [1]. After appropriate 
institutional review board ethical approval, consecutive non-metastatic (M0) RCC patients treated 
surgically with curative intent between 1st January 2006 and 31st Dec 2011 were included by 
retrospective patient encrypted data collection in an Excel file according to our RECUR protocol. 
This time frame was chosen for 2 reasons: (1) Targeted therapy was only introduced from 2006 
onwards, i.e. limiting the study period to after 2006 excluded patients not considered for targeted 
therapeutic options, which may have influenced RCC recurrence outcomes. (2) Limiting the study to 
the end of 2011 enabled a minimum of 4 years of follow-up data to be accrued considering that first 
set of data collection started in beginning of 2016. Patients that died or recurred within 4 years of FU 
were included for the analyses. Patients that did not die or recur were excluded if their FU was less 
than 4 years. Data lock for the current analysis was on May 1st 2017. 
Overall, 1,889 patients were included in RECUR. 164 were excluded from the analysis due to lack of 
baseline data or death <90 days after primary surgery. Furthermore, 111 patients were excluded due 
to follow-up <4 years and finally, 53 were excluded due to lack of follow-up imaging data. 
Table A (below) shows the centers with patients included in the study. 
All subtypes of RCC were recorded according to the RECUR protocol and for the current study. 
M0 was defined as preoperative imaging not revealing any signs of metastatic disease in the chest or 
abdomen. Baseline characteristics (gender, age and type of surgery), tumor (side, size and histology), 
Type of surgery (radical nephrectomy (RN), partial nephrectomy (PN), either open, laparoscopic or 
robot assisted), number and type of imaging to recurrence or last FU (Computed Tomography (CT) 
abdomen, CT chest, plain chest X-ray (CXR), Ultrasound (US) and magnetic resonance imaging (MRI)), 
recurrence characteristics (time to recurrence, site, symptoms, exact dates of all FU imaging leading 
detection of recurrence and detection modality) and their intent (curative, palliative or observation 
only) and subsequent management (focal: none, metastasectomy, radiotherapy or ablative, 
systemic; none, anti-vascular endothelial growth factor (anti-VEGF)/tyrosine kinase inhibitors (TKI), 
Mammalian Target of Rapamycin inhibitor (mTOR), monoclonal antibody (mAB), Immunotherapy 
(interferon) or best supportive care) together with survival outcomes (alive, free of RCC, alive with 
RCC, death due to RCC, death by other cause) were recorded from medical records.
Patients who died within 90 days after primary surgery were excluded as their deaths were 
considered as most likely postoperative complications and/or risk of introducing a staging bias on 
mortality rates. The 7th edition of the American Joint Committee on Cancer (AJCC) tumor node 
metastasis (TNM) classification from 2010 was used [3]. It has to be acknowledged that the staging of 
lymph nodes has changed since the introduction of the Leibovich score. However, as both pN1 and 
Page 28 of 29
URL: http://mc.manuscriptcentral.com/sjun  Email: ISJU-peerreview@journals.tandf.co.uk
Scandinavian Journal of Urology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Dabestani, Beisland et al. (2019); Increased use of cross-
sectional imaging for follow-up does not improve post-
recurrence survival of surgically treated initially localized RCC: 
results from a European multicenter database (RECUR).
pN2 receive an equal amount of points in the score a reclassification with an older TNM was not 
necessary. In patients with two ipsilateral or contralateral tumors undergoing surgery, the clinical 
and histological features of the largest and/or most aggressive tumor were used for the analysis. 
Patients with hereditary disease (e.g. Von Hippel-Lindau, Birt-Hogg-Dubé syndrome and Hereditary 
Papillary Renal Cell Carcinoma) were excluded as were benign tumors (e.g. angiomyolipoma and 
oncocytoma).
Patients were stratified into low, intermediate and high risk groups by Leibovich score in cases of 
predominantly clear cell RCC (ccRCC) and Union Internationale Contre le Cancer(UICC)/AJCC score if a 
non-clear cell RCC (non-ccRCC) subtype, i.e. papillary RCC (pRCC), chromophobe RCC (chRCC), or 
other types of RCC (oRCC) were present [3, 4]. Presence of sarcomatoid RCC (sRCC) was additionally 
registered. Isolated local, solitary and oligometastatic (≤3 lesions at a single site) recurrences were 
considered potentially curable (PC) by local therapeutic strategies while all others were regarded as 
probably incurable (PI), i.e. >3 lesions at a single site or dissemination to ≥2 distant sites. Definition of 
local recurrence was for PN, a local recurrence in the kidney parenchyma while local recurrence in 
patients with RN was any recurrence in the renal bed not including peritoneal recurrence (which 
indicated disseminated disease) nor hilar lymph node metastases (which were defined as 
retroperitoneal recurrences) in our database. For detection of recurrences, CT and MRI were 
considered cross-sectional imaging modalities while CXR, US and clinical examination were 
considered conventional. Whether patients were symptomatic at time point of recurrence detection 
and whether recurrences were detected within or outside the respective institutions FU protocols 
were also recorded. Time points of FU imaging collected were based on FU protocols of respective 
treating centers and their local standards.
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Table A – Number of RCC cases per center in RECUR database
Institute/center Country N total N 
excluded
N 
recurrence
Skane University Hospital Sweden 308 15 52
Umea University Hospital Sweden 151 6 32
Landspitali University 
Hospital Iceland 161 30 29
Edinburgh University United Kingdom 277 131 35
University of Aberdeen United Kingdom 150 31 34
Haukeland University 
Hospital Norway 249 2 25
UMCU/NCI The Netherlands 186 11 44
Coimbra University Hospital Portugal 150 4 29
Cabueñes University 
Hospital Spain 131 1 35
San Agustin University 
Hospital Spain 73 1 13
UEP Italy 53 45 8
Total NA 1889 277 336
NA = Not Applicable. NCI = National Cancer Institute, Amsterdam. UEP = University 
of Eastern Piedmont, Novara. UMCU = University Medical Center Utrecht
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